Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 1, 2014 - Issue 4
Submit an article Journal homepage
525
Views
1
CrossRef citations to date
0
Altmetric
AUTHOR'S VIEW

Triple threat treatment: Exploiting the dependence receptor properties of metabotropic glutamate receptor 1 against melanoma

Tara GelbFrom the Department of Pharmacology and Physiology; Georgetown University; Washington, DCUSACorrespondence[email protected]
,
Hannah A HathawayFrom the Department of Pharmacology and Physiology; Georgetown University; Washington, DCUSA
&
Jarda T WroblewskiFrom the Department of Pharmacology and Physiology; Georgetown University; Washington, DCUSA
Article: e969163 | Received 21 Aug 2014, Accepted 22 Aug 2014, Published online: 31 Dec 2014

References

  • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093
  • Gelb T, Pshenichkin S, Rodriguez OC, Hathaway HA, Grajkowska E, DiRaddo JO, Wroblewska B, Yasuda RP, Albanese C, Wolfe BB, et al. Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas. Oncogene 2014; 1-10; PMID:25065592; http://dx.doi.org/10.1038/onc.2014.231
  • Shin S, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S. Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res 2008; 21:368-78; PMID:18435704; http://dx.doi.org/10.1111/j.1755-148X.2008.00452.x
  • Wangari-Talbot J, Wall BA, Goydos JS, Chen S. Functional effects of GRM1 suppression in human melanoma cells. Mol Cancer Res 2012; 10:1440-50; PMID:22798429; http://dx.doi.org/10.1158/1541-7786.MCR-12-0158
  • Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS, Chen S. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007; 67:2298-305; PMID:17332361; http://dx.doi.org/10.1158/0008-5472.CAN-06-3665
  • Goldschneider D, Mehlen P. Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 2010; 29:1865-82; PMID:20173780; http://dx.doi.org/10.1038/onc.2010.13
  • Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA, Goydos JS. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 2010; 130:2240-9; PMID:20505744; http://dx.doi.org/10.1038/jid.2010.126
  • Pshenichkin S, Dolińska M, Klauzińska M, Luchenko V, Grajkowska E, Wroblewski JT. Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation- possible role as a dependence receptor. Neuropharmacology 2008; 55:500-8; PMID:18619982; http://dx.doi.org/10.1016/j.neuropharm.2008.06.039
  • Emery AC, Pshenichkin S, Takoudjou GR, Grajkowska E, Wolfe BB, Wroblewski JT. The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, beta-arrestin-1-dependent ERK phosphorylation. J Biol Chem 2010; 285:26041-8; PMID:20566651; http://dx.doi.org/10.1074/jbc.M110.139899

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.